½ÃÀ庸°í¼­
»óǰÄÚµå
1279782

¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : µ¿¹° À¯Çüº°, Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Veterinary Regenerative Medicine Market Size study & Forecast, by Animal Type by Product, by Application, by End Use and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿¹°¿ë Àç»ýÀÇ·á ºÐ¾ß¿¡¼­´Â µ¿¹°¿¡ ´ëÇÑ »õ·Î¿î ¼¼Æ÷ ¹× Á¶Á÷ Ä¡·á¹ýÀÌ È°¹ßÈ÷ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Ä¡·á¿¡ »ç¿ëµÇ´Â ¹°Áú·Î µ¿¹°ÀÇ ¼¼Æ÷, Á¶Á÷, ¼¼Æ÷ ¹× Á¶Á÷ À¯·¡ Á¦Ç°(¾àĪ ACTP)ÀÌ ÀÖ½À´Ï´Ù. ¼¼Æ÷³ª Á¶Á÷À» Æ÷ÇÔÇϰųª Æ÷ÇÔÇϰųª ¼¼Æ÷³ª Á¶Á÷¿¡¼­ À¯·¡ÇÑ µ¿¹°¿¡°Ô ¾ÈÀüÇÑ Á¦Ç°À» ÀÌ ´Ü¾î·Î Ç¥ÇöÇϰí ÀÖ½À´Ï´Ù. µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀåÀº ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ ÁöÃâ Áõ°¡¿Í µ¿¹°¿ë Àç»ýÀÇ·á ¿¬±¸°³¹ßÀÇ È°¼ºÈ­·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ µ¿¹°¿ë Àç»ýÀÇ·á´Â ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°è¿¡¼­ ¹Ý·Áµ¿¹°À» ±â¸£´Â °¡Á¤ÀÌ ´Ã¾î³ª¸é¼­ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ¹Ý·Áµ¿¹° ¿ëǰ ÇùȸÀÇ 2021³â Á¶»ç¿¡ µû¸£¸é ¹Ì±¹¿¡¼­ ¹Ý·Á°ßÀ» Ű¿ì´Â °¡±¸´Â 6,900¸¸ °¡±¸¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. APPA Á¶»ç 2021-2022¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¾à 9,050¸¸ °¡±¸, 70%°¡ ¹Ý·Áµ¿¹°À» Ű¿ì°í ÀÖÀ¸¸ç, ÃÖ±Ù °¡Á·, ƯÈ÷ ÇÙ°¡Á· »çÀÌ¿¡¼­ ¹Ý·Áµ¿¹°À» ±â¸£´Â °ÍÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡¿Í ÇÔ²² ¹Ý·Áµ¿¹°ÀÇ ±Þ¼º ¹× ¸¸¼ºÁúȯÀÇ À¯Çà°ú ÀÌ Áö¿ªÀÇ ÁÖ¿ä ±â¾÷µéÀÇ Á¦Ç° °³¹ß Ȱµ¿ Áõ°¡·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì, ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ¹Ý·Áµ¿¹° »çÀ° Àα¸ Áõ°¡¿Í ÁÖ¿ä ½ÃÀå Âü¿©ÀÚµéÀÇ È°¹ßÇÑ R&D Ȱµ¿À¸·Î ÀÎÇØ ¸ÅÃâ ±âÁØÀ¸·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÅÈï ½ÃÀåÀÇ ¹ßÀü, ÀǾàǰ °³¹ßÀ» À§ÇÑ °øµ¿ ¿¬±¸ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ª È®Àå, Á¤ºÎ ±â°ü ¹× ºñ¿µ¸® ´Üü ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¼ö³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí ÇâÈÄ ¼ö³â°£ÀÇ °¡Ä¡¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í µ¿¹° Á¾º° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇԵ˴ϴÙ.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ½º³À¼ô
  • ¼¼°è ½ÃÀ塤ºÎ¹®º° ½ÃÀå Ã߻ꡤ¿¹Ãø, 2019-2029³â
    • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, Áö¿ªº°, 2019-2029³â
    • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : µ¿¹° À¯Çüº°, 2019-2029³â
    • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : Á¦Ç°º°, 2019-2029³â
    • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : ¿ëµµº°, 2019-2029³â
    • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : ÃÖÁ¾ »ç¿ëº°, 2019-2029³â
  • ÁÖ¿ä µ¿Çâ
  • ¿¹Ãø ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • º» Á¶»çÀÇ ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • º» Á¶»çÀÇ ´ë»ó ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå ¿ªÇÐ

  • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀåÀÇ ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ ÁöÃâÀÇ Áõ°¡
      • µ¿¹°¿ë Àç»ýÀÇ·á¿¡¼­ ¿¬±¸°³¹ßÀÇ Áõ°¡
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • µ¿¹°¿ë Àç»ýÀÇ·áÀÇ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • ¹Ý·Áµ¿¹°¿¡¼­ ±Þ¼º¡¤¸¸¼ºÁúȯÀÇ ¸¸¿¬
      • ÁÖ¿ä ±â¾÷º° ±¸»óÀÇ Áõ°¡

Á¦4Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's 5 Force ¸ðµ¨ÀÇ ¹Ì·¡Àû ¾îÇÁ·ÎÄ¡(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è Àü¹®°¡º° Àü¸Á
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¸®½ºÅ© Æò°¡ : COVID-19ÀÇ ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡ ¹ÌÄ¡´Â ÀüüÀûÀÎ ¿µÇâ¿¡ °üÇÑ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ¼öÀÇ¿ë Àç»ýÀÇ·á ¼¼°è ½ÃÀå, µ¿¹° À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, µ¿¹° À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, µ¿¹° À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2019-2029³â
  • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¼Òµ¿¹°
    • ´ëÇü µ¿¹°

Á¦7Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : Á¦Ç°º°, ¼º´É - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø 2019-2029³â
  • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Áٱ⼼Æ÷
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ¿ëµµº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ¿ëµµº° ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Á¤Çü¿Ü°ú
    • ¿Ü»ó¡¤Ã¢»ó Ä¡·á
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : ÃÖÁ¾ »ç¿ëº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : ÃÖÁ¾ »ç¿ëº°) ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ÃÖÁ¾ »ç¿ëº° ÃßÁ¤¡¤¿¹Ãø 2019-2029³â
  • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • µ¿¹°º´¿ø/Ŭ¸®´Ð
    • µ¿¹°¿ë ¿¬±¸±â°ü

Á¦10Àå ¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : Áö¿ªº° ºÐ¼®

  • µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • µ¿¹° À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • Á¦Ç° À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ÃÖÁ¾ »ç¿ëº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
    • ij³ª´Ù
  • À¯·´ÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • ¼¼°èÀÇ ±âŸ Áö¿ª

Á¦11Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Boehringer Ingelheim International Gmbh
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫 Á¤º¸(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù °³¹ß »óȲ
    • Zoetis
    • Dechra
    • Acell Inc.(Integra Lifesciences)
    • Vetherapy
    • Vetstem, Inc.
    • Ardent
    • Enso Discoveries
    • Animal Cell Therapies, Inc.
    • Vetbiologics

Á¦12Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ¹ë¸®µ¥À̼Ç
    • ÃâÆÇ
  • Á¶»çÀÇ Æ¯Â¡
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
KSA 23.06.12

Global Veterinary Regenerative Medicine Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. New cell and tissue therapies for animals are actively being researched in the field of veterinary regenerative medicine. Animal cells, tissues, and cell- and tissue-based products, or ACTPs for short, are the substances used in these treatments. Animal-safe products that contain, include, or arise from cells or tissues are referred to by this phrase. The Veterinary Regenerative Medicine market is expanding because of increasing pet expenditure and growing Research and development in veterinary regenerative medicine. However, high Cost of Veterinary Regenerative Medicine may halt market growth.

Rising adoption of pet across the world is favouring the market growth. For instance: according to a 2021 survey by the American Pet Products Association, there are 69 million dog-owning households in the United States. Adopting pets has therefore recently gained popularity among families, especially nuclear families. Approximately 90.5 million households in the United States, or 70%, have pets, according to the APPA Survey 2021-2022. Along with these rise in research and development activities, prevalence of acute & chronic diseases in pets and rising initiatives by the key players for product development activities in the region is creating a lucrative growth to the market.

The key regions considered for the Global Veterinary Regenerative Medicine Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising pet adoption, rising research, and product development activities by key market players. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for medicine development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • Boehringer Ingelheim International Gmbh
  • Zoetis
  • Dechra
  • Acell Inc. (Integra Lifesciences)
  • Vetherapy
  • Vetstem, Inc.
  • Ardent
  • Enso Discoveries
  • Animal Cell Therapies, Inc.
  • Vetbiologics

Recent Developments in the Market:

  • In September 2021, Dechra acquired marketing and distribution rights of ProVet BMC and ProVet APC systems from Hassinger Biomedical. These patented medical devices helped the company expand its equine product line and boosted its market position in the veterinary regenerative medicine market.

Global Veterinary Regenerative Medicine Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Animal Type, Product, Application, End Use, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Animal Type offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Animal Type:

  • Small Animals
  • Large Animals

By Product:

  • Stem Cells
  • Others

By Application:

  • Orthopedics
  • Trauma/Wound Care
  • Others

By End Use:

  • Veterinary Hospitals/Clinics
  • Veterinary Research Institutes

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Veterinary Regenerative Medicine Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Veterinary Regenerative Medicine Market, by Animal Type, 2019-2029 (USD Billion)
    • 1.2.3. Veterinary Regenerative Medicine Market, by Product, 2019-2029 (USD Billion)
    • 1.2.4. Veterinary Regenerative Medicine Market, by Application, 2019-2029 (USD Billion)
    • 1.2.5. Veterinary Regenerative Medicine Market, by End Use, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Veterinary Regenerative Medicine Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Veterinary Regenerative Medicine Market Dynamics

  • 3.1. Veterinary Regenerative Medicine Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing pet expenditure
      • 3.1.1.2. Growing Research and development in veterinary regenerative medicine
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of Veterinary Regenerative Medicine
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Prevalence of acute & chronic diseases in pets
      • 3.1.3.2. Rising initiatives by the key players

Chapter 4. Global Veterinary Regenerative Medicine Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Veterinary Regenerative Medicine Market, by Animal Type

  • 6.1. Market Snapshot
  • 6.2. Global Veterinary Regenerative Medicine Market by Animal Type, Performance - Potential Analysis
  • 6.3. Global Veterinary Regenerative Medicine Market Estimates & Forecasts by Animal Type 2019-2029 (USD Billion)
  • 6.4. Veterinary Regenerative Medicine Market, Sub Segment Analysis
    • 6.4.1. Small Animals
    • 6.4.2. Large Animals

Chapter 7. Global Veterinary Regenerative Medicine Market, by Product

  • 7.1. Market Snapshot
  • 7.2. Global Veterinary Regenerative Medicine Market by Product, Performance - Potential Analysis
  • 7.3. Global Veterinary Regenerative Medicine Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
  • 7.4. Veterinary Regenerative Medicine Market, Sub Segment Analysis
    • 7.4.1. Stem Cells
    • 7.4.2. Others

Chapter 8. Global Veterinary Regenerative Medicine Market, by Application

  • 8.1. Market Snapshot
  • 8.2. Global Veterinary Regenerative Medicine Market by Application, Performance - Potential Analysis
  • 8.3. Global Veterinary Regenerative Medicine Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
  • 8.4. Veterinary Regenerative Medicine Market, Sub Segment Analysis
    • 8.4.1. Orthopedics
    • 8.4.2. Trauma/Wound Care
    • 8.4.3. Others

Chapter 9. Global Veterinary Regenerative Medicine Market, by End Use

  • 9.1. Market Snapshot
  • 9.2. Global Veterinary Regenerative Medicine Market by End Use, Performance - Potential Analysis
  • 9.3. Global Veterinary Regenerative Medicine Market Estimates & Forecasts by End Use 2019-2029 (USD Billion)
  • 9.4. Veterinary Regenerative Medicine Market, Sub Segment Analysis
    • 9.4.1. Veterinary Hospitals/Clinics
    • 9.4.2. Veterinary Research Institutes

Chapter 10. Global Veterinary Regenerative Medicine Market, Regional Analysis

  • 10.1. Veterinary Regenerative Medicine Market, Regional Market Snapshot
  • 10.2. North America Veterinary Regenerative Medicine Market
    • 10.2.1. U.S. Veterinary Regenerative Medicine Market
      • 10.2.1.1. Animal Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.2. Product Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.3. Application breakdown estimates & forecasts, 2019-2029
      • 10.2.1.4. End Use breakdown estimates & forecasts, 2019-2029
    • 10.2.2. Canada Veterinary Regenerative Medicine Market
  • 10.3. Europe Veterinary Regenerative Medicine Market Snapshot
    • 10.3.1. U.K. Veterinary Regenerative Medicine Market
    • 10.3.2. Germany Veterinary Regenerative Medicine Market
    • 10.3.3. France Veterinary Regenerative Medicine Market
    • 10.3.4. Spain Veterinary Regenerative Medicine Market
    • 10.3.5. Italy Veterinary Regenerative Medicine Market
    • 10.3.6. Rest of Europe Veterinary Regenerative Medicine Market
  • 10.4. Asia-Pacific Veterinary Regenerative Medicine Market Snapshot
    • 10.4.1. China Veterinary Regenerative Medicine Market
    • 10.4.2. India Veterinary Regenerative Medicine Market
    • 10.4.3. Japan Veterinary Regenerative Medicine Market
    • 10.4.4. Australia Veterinary Regenerative Medicine Market
    • 10.4.5. South Korea Veterinary Regenerative Medicine Market
    • 10.4.6. Rest of Asia Pacific Veterinary Regenerative Medicine Market
  • 10.5. Latin America Veterinary Regenerative Medicine Market Snapshot
    • 10.5.1. Brazil Veterinary Regenerative Medicine Market
    • 10.5.2. Mexico Veterinary Regenerative Medicine Market
    • 10.5.3. Rest of Latin America Veterinary Regenerative Medicine Market
  • 10.6. Rest of The World Veterinary Regenerative Medicine Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Boehringer Ingelheim International Gmbh
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Zoetis
    • 11.2.3. Dechra
    • 11.2.4. Acell Inc. (Integra Lifesciences)
    • 11.2.5. Vetherapy
    • 11.2.6. Vetstem, Inc.
    • 11.2.7. Ardent
    • 11.2.8. Enso Discoveries
    • 11.2.9. Animal Cell Therapies, Inc.
    • 11.2.10. Vetbiologics

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦